Inhibitor and substrate binding by New Delhi metallo-beta-lactamase-1: a molecular dynamics studies

Curr Comput Aided Drug Des. 2014;10(3):197-204. doi: 10.2174/1574886309666141126145225.

Abstract

The control of beta-lactam antibiotics released through the inhibition of the New Delhi metallo-beta-lactamase 1 (NDM-1) has been identified as a potential target for the treatment of the muti-drugs resistance (MDR) bacteria disease. We have employed molecular dynamics (MD), alanine-scanning mutagenesis and molecular docking techniques to optimize the x-ray NDM-1 structure with 11 drugs (Tigecycline, BAL30072, D-captopril, Penicillin G, Ampicillin, Carbenicillin, Cephalexin, Cefaclor, Nitrocefin, Meropenem, and Imipenem). From our simulations, we found that the 5 residues Asp223, His120, His122, His162 and His189 are responsible for the selectivity of NDM-1 associated drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • beta-Lactamase Inhibitors / pharmacology
  • beta-Lactamases / chemistry
  • beta-Lactamases / drug effects*
  • beta-Lactams / pharmacology*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • beta-Lactams
  • beta-Lactamases
  • beta-lactamase NDM-1